Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.
Roy M FleischmannRicardo BlancoFilip E Van den BoschLouis BessetteYanna SongSara K PennErin McDearmon-BlondellNasser KhanKelly ChanEduardo MyslerPublished in: Rheumatology and therapy (2024)
NCT02629159.